HHSN261201400048C; TOPIC 309 ? ?DEVEL.OF.LOW COST,SMALLSAMPLE MULTI-ANAL.TECH.FORCANCER DIAGNOSIS,PROGNOSIS&EARLY DETECTION?;TITLE: DEPLOYMENT.OF.PROTOTYPE SYSTEM FOR DETECTION OF MULTI. ANAL. IN SMAL
HHSN261201400048C; TOPIC 309 ? ?DEVEL.OF.LOW COST,SMALLSAMPLE MULTI-ANAL.TECH.FORCANCER DIAGNOSIS,PROGNOSIS&EARLY DETECTION?;TITLE: DEPLOYMENT.OF.PROTOTYPE SYSTEM FOR DETECTION OF MULTI. ANAL. IN SMAL
批准号:
8942697
负责人:
ARTHUR TINKELENBURG
金额:
$100.0万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-16 至 2016-09-15
关键词:
AnusAutomationBiopsy SpecimenCell physiologyClinicalColorectal CancerComputer softwareDataData AnalysesDetectionDevelopmentDiagnosisDisease ProgressionEarly DiagnosisImage AnalysisImmunologyImmunotherapyInstitutesLaboratoriesMemorial Sloan-Kettering Cancer CenterPatientsPhaseSamplingSystemTechniquesTechnologyTestingTissuesUniversitiescancer diagnosiscancer immunotherapycostexperiencenoveloptical imagingoutcome forecastprototyperesponsesoftware development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This proposal will build on the successful efforts from Phase I, which served to characterize the technology's
accuracy and limits of detection and provide proof of concept data on mucosal biopsy samples from patients
with colorectal cancer. We aim to (1) Develop a prototype analytical system incorporating Enumeral's
technology, including automation, software and data analysis and (2)Test prototypes on clinical samples in
collaborating academic laboratories to demonstrate clinical utility and advantages over analytical current
techniques.
Our collaborators include Jedd Wolchok (Memorial Sloan Kettering Cancer Center), who led clinical efforts for
breakthrough cancer immunotherapies ipilimumab and nivolumab, Douglas Kwon (Ragon Institute), whose lab
has expertise in mucosal immunology and extensive experience with Enumeral's technology; Elizabeth Hillman
(Columbia University), who has expertise in developing novel optical imaging systems; Jason Ruan (VigeneTech)
who is an expert in image analysis and software development, and Paul and Doug Sabin (Fikst) who are experts
in produce development.
The use of Enumeral's platform to understand cellular function and responses to therapy in resident tissues can
potentially have a significant impact on early cancer diagnosis, understanding mechanisms of disease
progression, and, ultimately development of novel, effective, and safe immunotherapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金